NewAmsterdam Pharma (NAMS) Operating Leases (2021 - 2026)

NewAmsterdam Pharma has reported Operating Leases for 5 years, with the latest figure at $66000.0 in Q4 2025.

• Quarterly Operating Leases fell 67.33% year-over-year to $66000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $66000.0 (down 67.33% YoY) and the FY2025 annual result came in at $66000.0, down 67.33% from the prior year.
• Operating Leases declined to $66000.0 in Q4 2025 per NAMS's latest filing, from $85000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $328000.0 in Q2 2024 and troughed at $57133.9 in Q4 2022.
• A 5-year average of $144080.6 and a median of $114990.4 in 2021 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases surged 370.65% in 2024, then slumped 68.6% in 2025.
• Over 5 years, Operating Leases stood at $126980.8 in 2021, then plunged by 55.01% to $57133.9 in 2022, then increased by 21.98% to $69691.2 in 2023, then soared by 189.85% to $202000.0 in 2024, then sank by 67.33% to $66000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $66000.0, $85000.0, and $103000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.